2025年7月，中国人民解放军总医院第七医学中心神经外科李萃萃主任团队成功为一名饱受13年顽固性 疼痛困扰的神经纤维瘤术后患者实施了脊髓电刺激手术，术后患者右下肢疼痛较前明显改善，为患者带 来了新的生活希望。 病例回顾 主诉：腰骶神经纤维瘤术后疼痛13年余 现病史：老年女性，2011年因右侧下肢放电样疼痛于外院行T11-S1椎管内神经纤维瘤病术，共切除23 个，左侧骶管旁因无症状暂未处理。术后，患者右下肢仍有持续放电样疼痛13年余，自臀部至侧，足背 外侧至足底，夜间影响睡眠，口服止痛药物效果不明显，近1年疼痛加重，夜间需药物辅助。为缓解疼 痛症状，患者寻求进一步治疗。 入院后，李萃萃主任为患者进行了全面的检查，诊断为右下肢顽固性疼痛，神经纤维瘤病，低白细胞血 症。经与患者及家属充分沟通，李萃萃主任决定为患者行脊髓电刺激植入手术，以改善其疼痛症状。 手术分两期进行，一期手术在术中影像的引导下，并依托术中电生理监测技术，成功为患者植入5-6-5 片状电极进行测试治疗。术后，团队根据电极植入位置及患者疼痛情况，为患者设置了合适的刺激靶 点、幅度、脉宽、频率等刺激参数，患者自述右下肢疼痛较前明显改善，遂决定进行二期永 ...

Group 1 - The stock price of Weisi Medical (688580) closed at 46.98 yuan on July 16, 2025, with an increase of 2.26% and a trading volume of 22,900 hands, resulting in a transaction amount of 106 million yuan [1] - On July 16, the net inflow of main funds was 9.67 million yuan, accounting for 9.09% of the total transaction amount, while retail investors had a net outflow of 4.53 million yuan, accounting for 4.25% [1][2] - The financing data shows that on July 16, the financing balance was 176 million yuan, with a net repayment of 5.61 million yuan [2][3] Group 2 - Weisi Medical's Q1 2025 report indicates a main revenue of 95.91 million yuan, a year-on-year increase of 9.4%, and a net profit of 33.22 million yuan, a year-on-year increase of 52.71% [5] - The company has a total market value of 4.499 billion yuan, with a net asset of 1.662 billion yuan and a net profit of 33.22 million yuan, ranking 75th, 82nd, and 51st respectively in the medical device industry [5] - The company aims to become a global leader in the magnetic stimulation field and a leading supplier in the rehabilitation and medical aesthetics sectors in China, while exploring overseas markets [5] Group 3 - Over the past 90 days, 9 institutions have rated the stock, with 6 buy ratings and 3 hold ratings, and the average target price set at 55.12 yuan [6] - The company maintains a gross profit margin of 66.65%, significantly higher than the industry average of 51.08%, and a net profit margin of 34.64%, compared to the industry average of 10.86% [5] - The company is focused on R&D in advanced technologies such as electrical stimulation, magnetic stimulation, electrophysiology, rehabilitation robots, and medical energy sources [5]

Core Viewpoint - Spinocerebellar ataxia type 3 (SCA3) is a common hereditary disorder with no effective treatment, leading to significant burdens on patients and healthcare systems [1][2]. Recent research indicates that transcranial alternating current stimulation (tACS) may provide a safe and effective intervention for improving symptoms in SCA3 patients [3][11]. Summary by Sections Disease Overview - SCA3 is caused by the expansion of CAG repeats in the ATXN3 gene, leading to progressive cerebellar ataxia, which manifests as unsteady gait, speech difficulties, swallowing problems, and poor motor accuracy [1]. - Most SCA3 patients lose mobility within 10-20 years of onset, with a survival period of 20-25 years from onset to death [2]. Recent Research Findings - A randomized controlled trial published in Cell Reports Medicine demonstrated that tACS is safe, effective, and well-tolerated, improving the severity of ataxia by modulating brain functional connectivity in SCA3 patients [3][11]. - The study involved 82 SCA3 patients, randomly assigned to receive either active tACS or sham stimulation for 2 weeks, with significant improvements observed in the active group [8]. Clinical Trial Details - The trial was a triple-blind, parallel-group, sham-controlled study assessing the effects of tACS on ataxia severity and quality of life, using functional MRI to evaluate changes in brain connectivity [7]. - Results showed that 80% of participants in the active tACS group met the primary outcome measure, compared to only 10% in the sham group, with significant reductions in SARA scores [8]. Implications for Future Treatment - The findings suggest that tACS could be a promising intervention for SCA3 and potentially other cerebellar disorders, highlighting the need for further research into its long-term effects [11].

脑机接口系列研究之产业专家视角：脑机接口与神经调控 进展 20250613 摘要 脑机接口技术通过解码大脑信号，实现对外部设备的控制，如机械臂和 语音合成，为截肢和失语症患者提供功能恢复的潜力，并可通过神经反 馈调控大脑功能。 中国在汉语语音解码方面取得显著进展，成功解码汉语语音并针对多声 调特点进行技术创新，表明中国在语言识别领域已达到国际先进水平。 脑电信号因其便捷、动态和高时间分辨率的优势，成为动态解码中最常 用的工具，通过时频域解析可挖掘大脑在不同状态下的节律特征，用于 解码运动意图和情绪状态。 神经调控技术扩展了传统脑机接口的应用，通过电刺激、磁刺激等方法 调控神经功能，已成功应用于癫痫、帕金森病等疾病的治疗，并探索阿 尔兹海默病等新领域。 闭环脑机接口通过将大脑信息反馈，动态调整控制策略，优化控制效果， 浙江大学利用闭环脊髓刺激帮助瘫痪患者康复，美国 FDA 批准闭环脑神 经电刺激设备投入使用。 Q&A 脑机接口技术的基础是什么？ 脑机接口技术的基础是神经解码和神经调控。人类和一些有完整神经系统的动 物能够产生正常行为，依赖于大脑的正常运转。大脑通过不断发送和接收各种 信息来实现这些功能，包括视觉 ...

2025.07. 10 本文字数：1513，阅读时长大约2.5分钟 作者 | 第一财经 钱童心 7月8日，国家卫健委网站发布通知，禁止将"颈深淋巴管/结—静脉吻合术"应用于阿尔茨海默病的治 疗；另一项通知禁止将"空肠回肠吻合术"应用于2型糖尿病治疗。 针对"颈深淋巴管/结—静脉吻合术"，通知提到，有个别医疗机构开展"颈深淋巴管/结—静脉吻合 术"治疗阿尔茨海默病，为进一步加强医疗技术临床应用管理，组织专家对该技术进行评估，评估认 为该技术处于临床研究早期探索阶段，适应症及禁忌症尚不明确，安全性、有效性缺乏高质量循证医 学证据支撑。 根据相关医院去年发布的微信公众号文章，2015年《自然》杂志首次证实"脑膜中功能性淋巴管的存 在"，基于此，"疏尔术"这种疗法应运而生，将患者脑部积淀的毒性蛋白通过淋巴疏通代谢，从而中 止患者病情的进一步恶化，保留现有的认知功能。 第一财经记者了解，上海合作开展"疏尔术"的两所医院的临床研究此前通过医院多轮伦理审查后，已 进入实施阶段。截至2024年6月10日，共有12名患者在上海接受了这一手术。 根据相关反馈，主要副作用是患者术后24小时内出现精神紊乱，可能是麻醉所致，在72小时 ...

Group 1 - The technology opens new avenues for treating refractory mental illnesses, including treatment-resistant depression, obsessive-compulsive disorder, and tic disorders [1][3] - A case study from Ruijin Hospital highlights a 32-year-old patient with a 16-year history of depression who benefited from a novel therapy combining deep brain stimulation (DBS) and brain-computer interface (BCI) technology [1] - The innovative treatment involves the implantation of two electrodes with 16 stimulation contacts into the brain's emotional circuit, allowing for precise modulation and breaking the cycle of depression [1][3] Group 2 - The DBS combined with BCI technology is a minimally invasive intervention that avoids the memory loss associated with electroconvulsive therapy and the side effects of long-term medication [3] - This new therapy has already been clinically applied to over 30 cases, providing a new option for treatment-resistant depression patients [3] - Depression is increasingly recognized as a significant mental health issue, particularly among younger populations, with a reported prevalence of 15% to 20% among adolescents in China [3]

Company Overview - Weisi Medical's closing price on July 9 was 45.03 yuan, down 1.27%, with a rolling PE ratio of 38.02 times and a total market value of 4.313 billion yuan [1] - The company ranks 80th in the medical device industry, which has an average PE ratio of 51.36 times and a median of 37.22 times [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.2201 million yuan, reflecting a year-on-year growth of 52.71% [1] - The sales gross margin stood at 66.65% [1] Shareholding Structure - As of the first quarter of 2025, five institutions held shares in Weisi Medical, including three other entities and two funds, with a total holding of 10.7452 million shares valued at 364 million yuan [1]

Company Overview - Weisi Medical's closing price on July 1 was 47.9 yuan, reflecting a 3.03% increase, with a rolling PE ratio of 40.44, marking a 16-day low, and a total market capitalization of 4.587 billion yuan [1] - The company specializes in the research, production, and sales of medical devices, with key products including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency [1] Financial Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, representing a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, up 52.71%, with a gross profit margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Industry Comparison - The average PE ratio for the medical device industry is 51.70, with a median of 37.36, placing Weisi Medical at the 81st position within the industry [1][2] - The static PE ratio for Weisi Medical is 44.99, and the price-to-book ratio is 2.76 [2]

"发现只是第一步，更重要的是及时干预。"上海交通大学医学院附属瑞金医院脑病中心副研究员张陈诚 对记者表示，如何方便患者居家治疗成为专家们探索的课题，TI(时间干涉)神经调控技术应运而生。张 陈诚介绍，TI神经调控技术通过多个头皮电极同步发出高频电流，在人的大脑深部情绪中枢(例如：杏 仁核)形成可控的低频干涉电场。这样，患者无需开颅、无需植入，就能被"精准干预"过度活跃的神经 回路。对那些拒绝或不耐受药物副作用的患者，TI神经调控技术提供了新的选择。 "患者参与度不够，我们在思考，能不能在'玩'里把治疗做完？"该院临床心理科副主任医师张晶璟的疑 问，催生了国内获二类医疗器械注册证的VR心理治疗产品——"虚拟人生"。据介绍，戴上VR眼罩后， 患者可以在6个至8个沉浸式场景里进行正念冥想、社交模拟、艺术创作等训练；医生端则可以实时接收 数据，洞悉情绪波动。该系统对失眠、焦虑等症状均有显著改善。张晶璟表示，"在游戏里疗愈"，治疗 再也不是一件"痛苦的事"。 来源：中国新闻网 中新网上海6月28日电 (记者 陈静)情绪X光机、TI神经调控技术、沉浸式 VR治疗系统、帕金森病自体干 细胞移植以及TIS无创深脑电刺激，这些 ...

Core Viewpoint - The rising prevalence of diabetes in China is leading to an increase in diabetic foot complications, with innovative treatments showing promise for improving patient outcomes [1][4]. Group 1: Diabetes Prevalence and Complications - The International Diabetes Federation projects that the number of diabetes patients aged 20-79 in China will exceed 164 million by 2030 [1]. - Among diabetes patients over 50, the annual incidence of diabetic foot is 8.1%, with a total amputation rate of 19.3% [1][2]. Group 2: Mechanisms of Diabetic Foot Development - High blood sugar causes progressive damage to foot tissues through vascular, nerve, and immune system impairments [2]. - Long-term high blood sugar leads to vascular damage, resulting in atherosclerosis and reduced blood flow to the feet, which can cause ischemia and necrosis [3][4]. Group 3: Innovative Treatment Approaches - Recent advancements include gene-engineered stem cell technology achieving over 96% wound healing rates in diabetic foot ulcers within 14 days [1]. - Breakthroughs in treatment methods such as antibiotic bone cement, spinal cord stimulation, and vascular reconstruction are providing new avenues for clinical intervention [1][4]. - Stem cell therapy and gene therapy are emerging as promising methods for improving blood flow and healing in diabetic foot patients [4][5]. Group 4: Clinical Symptoms and Warning Signs - Symptoms such as coldness, numbness, and changes in skin color are indicators of potential diabetic foot complications [7][8]. - Patients should be vigilant for signs of ulcers, which often originate from minor injuries, and seek immediate medical attention if systemic symptoms like fever occur [8][9].